by bbadmin | May 11, 2018 | Blog, CBD and Hemp, Regulatory Law
On April 23, 2018, Brownson • Norby, PLLC submitted to FDA a comment regarding cannabidiol (“CBD”). Brownson • Norby, PLLC Comment to FDA. The comment was in response to FDA’s April 9, 2018 request for input from stakeholders, the cannabis industry,...
by bbadmin | May 11, 2018 | Blog, CBD and Hemp, Regulatory Law
This week state authorities from Wisconsin and Michigan issued statements regarding the legal status of CBD, which can be found here: Michigan Department of Licensing and Regulatory Affairs Statement and Wisconsin Attorney General Statement Michigan On May 10, 2018,...
by bbadmin | May 8, 2018 | News
Last weekend we finally had some great weather, which was perfect for the Lifto de Mayo CrossFit Competition that we cosponsored. Events included lunging while holding a log on your shoulder, pull-ups and muscle-ups, running, “clusters” and powercleaning a...
by bbadmin | Apr 20, 2018 | Blog, CBD and Hemp, Regulatory Law
Earlier this month, on April 9, 2018, FDA published a notice requesting comments from the public on the scheduling of cannabis-related substances (“Cannabis Plant and Resin; Extracts and Tinctures of Cannabis; Delta-9-Tetrahydrocannabinol; Stereoisomers of...
by bbadmin | Apr 16, 2018 | Blog, Regulatory Law
FDA has released another revision to Ingredient Listing Guidance (found here), which clarifies some longstanding issues surrounding the listing requirements (previously created for traditional tobacco products) as applied to ENDS products. The first major point...
Recent Comments